01The core difference from solid phase
In solid phase synthesis the peptide is built on an insoluble resin, so excess reagents are removed by washing. In solution phase the peptide is dissolved, and every reagent must be removed by extraction, crystallisation or chromatography. That single difference drives everything else: purification burden, solvent volumes, cycle time and cost curve.
Solid phase wins on convenience for long sequences. Solution phase wins when you need quantity, when the sequence is short, or when the chemistry required is incompatible with a resin linker. The two are not rival ideologies; they are different toolkits.
02Where solution phase is the right choice
Three situations favour it. First, scale: reagent costs and reactor throughput become favourable once you are making hundreds of grams rather than milligrams. Second, short sequences, where the purification burden per residue is manageable. Third, fragments destined for convergent assembly, where protected peptides are needed as building blocks.
Fragments are the most interesting case. A long sequence can be assembled from two or three solution-phase fragments, each purified before coupling. This is how very long peptides are made without accumulating deletion errors across forty coupling steps.
03Protecting groups and the orthogonal problem
Every reactive side chain needs protection, and the strategy has to be orthogonal: the group removed at the end must not disturb the groups removed earlier. Boc and Fmoc chemistries both appear in solution work, with different acid sensitivities and different cleavage cocktails.
The practical difficulty is that each deprotection is a chance to lose material and to generate impurities that differ by a single protecting group. A certificate for a solution-phase product should therefore report purity by a method capable of resolving those near-neighbours, which usually means gradient high-performance liquid chromatography with a shallow slope.
04Coupling, racemisation and the epimer problem
Coupling in solution allows better mixing and monitoring than on resin, which is one reason solution routes can achieve high coupling efficiency. The risk that does not go away is racemisation at the activated residue, particularly for cysteine and for residues adjacent to bulky side chains.
Racemisation produces a diastereomer with nearly identical physical properties, so it hides in a purity figure unless the chromatographic method resolves it. Additives that suppress racemisation are standard, and a supplier who can describe which one was used is describing a real process rather than a catalogue entry.
05Purification: the cost centre
Crude solution-phase product contains unreacted fragments, deleted sequences, protected intermediates and reagents. Preparative chromatography is usually necessary, sometimes twice, and the yield loss is where the economics are decided.
This is why 'solution phase' on a product page is not automatically a quality signal. The meaningful questions are what the crude purity was, what method was used to purify, and what the final purity is by which method. Without those three, the synthetic route is a footnote.
06Reading a supplier's claim
Ask for the synthetic route in one sentence, the purification method, the final purity with method details, and the counter-ion. The counter-ion is the detail most often omitted and most often relevant: a trifluoroacetate salt and an acetate salt of the same peptide are not interchangeable in an assay.
If the answer is a marketing paragraph rather than four specifics, treat the route claim as unverified. The chemistry is checkable; the question is whether the supplier has the records to check it against.
07Scale economics in one paragraph
['Solution-phase synthesis has a different cost curve from solid-phase. Reagent cost per gram falls as batch size grows, while purification cost per batch stays roughly fixed. The crossover point is where the two curves meet, and it usually sits in the hundreds-of-grams range for short sequences.', 'Below that point, solid-phase is cheaper because purification is simpler. Above it, solution-phase wins because the reagent savings outrun the chromatography. This is why the same supplier may offer a short peptide made either way depending on the quantity ordered.', "The buyer-visible consequence is that a small order of a 'solution-phase' product is often the most expensive way to buy that compound, and the route claim is doing marketing work rather than describing an economic advantage."]08Impurity profiles worth asking about
['Solution-phase products carry a characteristic impurity profile: deletion sequences, partially deprotected intermediates, and diastereomers from racemisation. A certificate that reports a single purity figure does not distinguish among them.', "The useful question is not 'what is the purity' but 'what does the chromatogram show besides the main peak'. A supplier who can describe the impurity profile is a supplier who looked at the data rather than the summary line.", 'This is also where a shallow gradient matters: impurities that differ by one protecting group elute close to the main peak, and a steep method can hide them inside the integration window.']09Frequently asked questions
Is solution phase synthesis higher quality than solid phase?
Neither route is intrinsically better. Quality depends on purification, method suitability and the records kept. Long sequences are usually better made on resin; short ones at scale often better in solution.
Why do solution-phase products cost more per gram at small scale?
Because purification is a fixed cost per batch. At milligram scale the chromatography dominates the price; the advantage only appears as batch size grows.
What is a counter-ion and why does it matter?
The salt form of the peptide after cleavage and purification. Trifluoroacetate and acetate behave differently in assays and in solubility, so the counter-ion should be stated on the certificate.
Can I tell from a certificate whether a peptide was made in solution?
Not usually. Certificates report identity, purity and method, not route. Ask the supplier directly and expect a specific answer about protecting groups and purification.